REG - Destiny Pharma PLC - Destiny Pharma appoints Dr Yuri Martina as CMO

Destiny PharmaAnnouncement

03/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220503:nRSC8807Ja&default-theme=true

RNS Number : 8807J  Destiny Pharma PLC  03 May 2022

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Destiny Pharma strengthens Executive Management Team with the appointment of
Dr Yuri Martina as Chief Medical Officer

 

Brighton, United Kingdom - 3(rd) May 2022 - Destiny Pharma plc (AIM:DEST), a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life-threatening infections, today announces
the appointment of Dr. Yuri Martina as Chief Medical Officer (CMO).

 

Yuri brings to Destiny Pharma more than 20 years' experience and an extensive
record of excellence in clinical development and successful interactions at
the highest levels with key regulatory, industry and government stakeholders
including the European Medicines Agency (EMA), the US Food and Drug
Administration (FDA) and the Japanese Pharmaceutical and Medical Device Agency
(PMDA).

 

Most recently, Yuri was Senior Vice President Development and deputy CMO at
Grünenthal Group where he was a key member of the Global R&D Leadership
and the Global Commercial Leadership Teams. Yuri has been responsible for
advancing the Grünenthal Group R&D pipeline, including two phase 3
assets, two phase 2 assets and several early and pre-clinical assets. Yuri has
also been a key member and driver in several in-licensing and out-licensing
activities and in the completion of the acquisition of Mestex AG.

 

From 2014 to 2017, Yuri was Vice President Development and Clinical Operations
in Shionogi Europe, where he was a key contributor to the approval of Mulpeo
(previously Lusutrombopag) and Cefiderocol.

 

Throughout his career, Yuri has gained a deep insight into global markets,
working in Europe, the US, Middle East and Asia and has contributed to more
than ten submissions for Marketing Authorisation Applications (MAA) to the EMA
and New Drug Applications (NDA) to the FDA.

 

Yuri is a Medical Doctor by background, and also holds a PhD in Genetics and
Molecular Biology, an MBA and a Master's in Project Management. Yuri is also a
fellow member of the Royal Society of Medicine.

 

Neil Clark, Chief Executive Officer, Destiny Pharma said: "Yuri is an
important new member of our team, as he brings the right skill sets to drive
the strategy, direction and execution of the Company's Phase 3 clinical
development plans as we move towards the next phase of our growth."

 

Dr. Yuri Martina, Chief Medical Officer, Destiny Pharma, said: "I very much
look forward to being an integral part of Destiny Pharma's leadership
management team at such a pivotal moment in the Company's history. I feel
privileged to be able to contribute to progressing the pipeline of our unique
late-stage clinical assets addressing patients' unmet needs and delivering on
the Company's strategy to build a world-leading infection prevention company."

 

ENDS

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (about:blank)

 

Optimum Strategic Communications  (about:blank)

Mary Clark / Manel Mateus /Vici Rabbetts

+44 (0) 208 078 4357

DestinyPharma@optimumcomms.com (about:blank)

 

finnCap Ltd (Nominated Advisor and Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SporCov, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF research projects.

For further information on the company, please visit www.destinypharma.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFSASIIAFIF